Straits Times Index
3,300.04 -3.15 (-0.10%) Nikkei
38,429.01 -406.09 (-1.05%) Hang Seng
18,479.37 -98.93 (-0.53%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,598.95 -925.07 (-1.46%) CMC Crypto 200
1,297.53 -67.60 (-4.95%)
Pfizer Inc. (PFE.F)
| Previous close | 26.20 |
| Open | 26.20 |
| Bid | 25.88 x 150000 |
| Ask | 25.86 x 150000 |
| Day's range | 25.70 - 26.29 |
| 52-week range | 23.57 - 37.45 |
| Volume | |
| Avg. volume | 9,212 |
| Market cap | 145.527B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.57 (5.99%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 2-Pfizer reports patient death in Duchenne gene therapy study
A young patient died due to cardiac arrest after receiving Pfizer's experimental gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
- Reuters
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial tested boys 2 years to less than 4 years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
Insider Monkey15 Best S&P 500 Dividend Stocks To Buy Now
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]
